Direct answer: semaglutide (Wegovy) still produces more average weight loss — roughly 15% of body weight in its pivotal trial versus 11.2% for the highest dose of orforglipron (Foundayo) — but orforglipron is a once-daily pill with no injections, no refrigeration, and no food or water restrictions. Since the FDA approved Foundayo on April 1, 2026, the practical question Dr. Bismah Irfan, MD hears in her Houston practice is no longer “which drug is stronger on paper” but “which one will I actually stay on” — and that answer differs from patient to patient. Here is the full comparison.
What Is Orforglipron (Foundayo)?
Orforglipron is the first oral GLP-1 receptor agonist that can be taken any time of day, with or without food and water. The FDA approved it under the brand name Foundayo on April 1, 2026, for adults with obesity, or overweight with at least one weight-related condition, alongside diet and activity changes.
The reason it took the industry this long to make a convenient GLP-1 pill is chemistry. Semaglutide and its relatives are peptides — fragile molecules that stomach acid digests, which is why they are normally injected. Orforglipron is a small-molecule drug, not a peptide, so it survives digestion on its own. That single difference removes the fasting ritual that made Rybelsus (the older oral semaglutide) inconvenient: Rybelsus must be taken on an empty stomach with a few sips of water, followed by a 30-minute wait before eating or drinking. Foundayo has none of those rules.
Orforglipron vs Semaglutide at a Glance
| Orforglipron (Foundayo) | Semaglutide (Wegovy / Ozempic) | |
|---|---|---|
| Form | Once-daily pill | Once-weekly injection |
| Food / water rules | None — any time of day | None (injection) |
| Avg. weight loss in pivotal trial | 7.5–11.2% at 72 weeks (dose-dependent) | ~15% at 68 weeks (Wegovy, STEP-1) |
| Molecule | Small molecule (non-peptide) | Peptide |
| Storage | Room temperature | Refrigeration (pens, vials) |
| Approved for type 2 diabetes | Not yet (application expected) | Yes (Ozempic) |
| Common side effects | GI — nausea, vomiting, constipation | GI — the same class effects |
The Weight-Loss Numbers, Honestly
In ATTAIN-1, the pivotal trial behind the approval (3,127 adults without diabetes, 72 weeks), orforglipron produced average weight loss of 7.5% at the 6 mg dose, 8.4% at 12 mg, and 11.2% at 36 mg, against 2.1% for placebo. Just over half of the patients on the top dose lost at least 10% of their body weight. Wegovy’s pivotal STEP-1 trial reported roughly 15% average loss at 68 weeks, and tirzepatide (Zepbound) has posted higher numbers still.
One caveat belongs next to every table like the one above: these are different trials, run in different years on different populations — not head-to-head comparisons. Cross-trial numbers are directionally useful and nothing more. What they do support is the practical hierarchy most obesity-medicine physicians work with today: injectables lead on raw efficacy, and orforglipron brings respectable, clinically meaningful weight loss in a format many more people will actually take consistently.
Adherence: the Quiet Deciding Factor
A medication only works at the rate people keep taking it. Needle aversion is real, refrigeration complicates travel, and a weekly injection is easy to postpone into oblivion. A pill that goes down with morning coffee removes those failure points — no sharps container, no cold chain, no injection technique to learn at all. In ATTAIN-1, discontinuations due to side effects ran 5.3–10.3% depending on dose, mostly from the same gastrointestinal effects the whole GLP-1 class shares; the numbers for injectables are broadly similar. The difference in the real world tends to come from everything around the medication, and that is where the pill quietly wins for a subset of patients.
Who Tends to Fit Which Option
- Orforglipron may fit patients who ruled out GLP-1 therapy over needles, travel frequently, want nothing in the refrigerator, or plateaued on the practical logistics of weekly injections rather than the medication itself.
- Semaglutide (or tirzepatide) may fit patients targeting the largest possible weight loss, those with type 2 diabetes (where Ozempic is approved and orforglipron is not yet), and patients already stable and comfortable on a weekly injection — switching a working protocol for convenience alone is rarely the right trade.
- Neither decision belongs to a chart. Kidney function, gallbladder history, thyroid cancer history, current medications, and insurance coverage all move the answer. This is a prescriber conversation, and the switch between agents needs a washout-and-titration plan, not a Monday-morning swap.
Where Retatrutide Fits Into This Picture
The pipeline behind these two is crowded, and the loudest name in it is retatrutide — Lilly’s triple-agonist injectable that posted the largest trial weight-loss numbers to date. It is still investigational, with approval unlikely before late 2027; we cover its status in what retatrutide is and whether it’s FDA-approved. The practical takeaway for 2026: orforglipron and semaglutide are what a physician can actually prescribe today.
The Bottom Line
Semaglutide remains the efficacy benchmark you can get today, and orforglipron turns GLP-1 therapy into a once-daily pill with no strings attached — the first time that sentence has been true. If you are weighing the two, the deciding inputs are your weight-loss target, your relationship with needles, your other conditions, and what your insurance will cover. Book a consultation with IVitality MD — in our medical weight-loss program, Dr. Irfan reviews your labs and history, screens for contraindications, and matches you to the GLP-1 option you are most likely to succeed on, whether that is a pill or a pen.
Medically reviewed by Dr. Bismah Irfan, MD — Functional & Integrative Medicine, Houston, TX. Last reviewed: July 2026.
Frequently Asked Questions
Is orforglipron (Foundayo) FDA approved?
Yes. The FDA approved Foundayo on April 1, 2026, for adults with obesity or overweight with a weight-related condition. It is the first oral GLP-1 that can be taken any time of day without food or water restrictions. Approval for type 2 diabetes is still pending.
Does orforglipron work as well as semaglutide?
In its pivotal ATTAIN-1 trial, the highest dose of orforglipron produced 11.2% average weight loss at 72 weeks, while Wegovy's pivotal trial reported roughly 15% at 68 weeks. These come from different studies rather than a head-to-head comparison, but injectable semaglutide is generally expected to deliver more weight loss, and the pill to be easier to stay on.
Is orforglipron the same as Rybelsus?
No. Rybelsus is oral semaglutide — a peptide that must be taken on an empty stomach with a 30-minute wait before eating. Orforglipron is a different, non-peptide molecule that survives digestion on its own, which is why Foundayo has no food, water, or timing rules.
Can I switch from semaglutide injections to Foundayo?
Sometimes, but it is a prescriber decision, not a pharmacy swap. The switch involves a transition plan and dose titration, and it makes the most sense when logistics — needles, refrigeration, travel — are what is limiting your consistency, rather than the medication's effect.